BRAF and prostate cancer: Subsequently, DTP cells have been identified in various experimental models after targeted therapy, including additional EGFR‐mutant NSCLC cell lines, MET‐amplified gastric cancer, BRAF‐mutant melanoma, prostate cancer, colorectal cancer, and HER2‐positive breast cancer.428, 429, 430, 431, 432, 433